295 related articles for article (PubMed ID: 25503172)
1. A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
Cinar P; Calkins SM; Venook AP; Kelley RK
Anticancer Res; 2014 Dec; 34(12):7357-60. PubMed ID: 25503172
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
4. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
[TBL] [Abstract][Full Text] [Related]
7. Targeted HER2 treatment in advanced gastric cancer.
Jørgensen JT
Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
[TBL] [Abstract][Full Text] [Related]
9. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Catenacci DV; Rosales M; Chung HC; H Yoon H; Shen L; Moehler M; Kang YK
Future Oncol; 2021 Apr; 17(10):1155-1164. PubMed ID: 33263418
[TBL] [Abstract][Full Text] [Related]
10. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
[TBL] [Abstract][Full Text] [Related]
11. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
[TBL] [Abstract][Full Text] [Related]
13. [Pembrolizumab with trastuzumab and chemotherapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomas with surexpression of HER2 and CPS≥1].
Lévêque I; Spitzer E
Bull Cancer; 2024 Feb; 111(2):130-132. PubMed ID: 38071114
[No Abstract] [Full Text] [Related]
14. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
15. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.
Dijksterhuis WPM; Verhoeven RHA; Meijer SL; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
Gastric Cancer; 2020 Jul; 23(4):579-590. PubMed ID: 31927675
[TBL] [Abstract][Full Text] [Related]
16. [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Shen L; Xu JM; Feng FY; Jiao SC; Wang LW; Li J; Guan ZZ; Qin SK; Wang JJ; Yu SY; Wang YJ; Jin YN; Tao M; Zheng LZ; Pan LX
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):295-300. PubMed ID: 23985260
[TBL] [Abstract][Full Text] [Related]
17. Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.
Jørgensen JT
World J Gastroenterol; 2014 Apr; 20(16):4526-35. PubMed ID: 24782605
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.
Sawaki A; Ohashi Y; Omuro Y; Satoh T; Hamamoto Y; Boku N; Miyata Y; Takiuchi H; Yamaguchi K; Sasaki Y; Nishina T; Satoh A; Baba E; Tamura T; Abe T; Hatake K; Ohtsu A
Gastric Cancer; 2012 Jul; 15(3):313-22. PubMed ID: 22179434
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer.
Cosson VF; Ng VW; Lehle M; Lum BL
Cancer Chemother Pharmacol; 2014 Apr; 73(4):737-47. PubMed ID: 24519752
[TBL] [Abstract][Full Text] [Related]
20. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
